Vogt, A and McDonald, PR and Tamewitz, A and Sikorski, RP and Wipf, P and Skoko, JJ and Lazo, JS
(2008)
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells.
Molecular Cancer Therapeutics, 7 (2).
330 - 340.
ISSN 1535-7163
|
Plain Text (licence)
Available under License : See the attached license file.
Download (1kB)
|
Abstract
Mitogen-activated protein kinase phosphatase (MKP)-1 is a dual-specificity phosphatase that negatively regulates the activity of mitogen-activated kinases and that is overexpressed in human tumors. Contemporary studies suggest that induction of MKP-1 during chemotherapy may limit the efficacy of clinically used antineoplastic agents. Thus, MKP-1 is a rational target to enhance anticancer drug activity, but suitable small-molecule inhibitors of MKP-1 are currently unavailable. Here, we have used a high-content, multiparameter fluorescence-based chemical complementation assay for MKP activity in intact mammalian cells to evaluate the cellular MKP-1 and MKP-3 inhibitory activities of four previously described, quinonebased, dual-specificity phosphatase inhibitors, that is, NSC 672121, NSC 95397, DA-3003-1 (NSC 663284), and JUN-1111. All compounds induced formation of reactive oxygen species in mammalian cells, but only one (NSC 95397) inhibited cellular MKP-1 and MKP-3 with an IC50 of 13 μmol/L. Chemical induction of MKP-1 by dexamethasone protected cells from paclitaxel-induced apoptosis but had no effect on NSC 95397. NSC 95397 phenocopied the effects of MKP-1 small inhibitory RNA by reversing the cytoprotective effects of dexamethasone in paclitaxel-treated cells. Isobologram analysis revealed synergism between paclitaxel and NSC 95397 only in the presence of dexamethasone. The data show the power of a well-defined cellular assay for identifying cell-active inhibitors of MKPs and support the hypothesis that small-molecule inhibitors of MKP-1 may be useful as antineoplastic agents under conditions of high MKP-1 expression. Copyright © 2008 American Association for Cancer Research.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
Article
|
Status: |
Published |
Creators/Authors: |
Creators | Email | Pitt Username | ORCID |
---|
Vogt, A | | | | McDonald, PR | | | | Tamewitz, A | | | | Sikorski, RP | | | | Wipf, P | pwipf@pitt.edu | PWIPF | | Skoko, JJ | | | | Lazo, JS | | | |
|
Date: |
1 February 2008 |
Date Type: |
Publication |
Journal or Publication Title: |
Molecular Cancer Therapeutics |
Volume: |
7 |
Number: |
2 |
Page Range: |
330 - 340 |
DOI or Unique Handle: |
10.1158/1535-7163.mct-07-2165 |
Schools and Programs: |
Dietrich School of Arts and Sciences > Chemistry |
Refereed: |
Yes |
ISSN: |
1535-7163 |
MeSH Headings: |
Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms--drug therapy; Breast Neoplasms--pathology; Cell Survival--drug effects; Cytoprotection--drug effects; Dexamethasone--antagonists & inhibitors; Dexamethasone--pharmacology; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm--drug effects; Drug Synergism; Dual Specificity Phosphatase 1--antagonists & inhibitors; Dual Specificity Phosphatase 1--metabolism; Dual Specificity Phosphatase 6--antagonists & inhibitors; Dual Specificity Phosphatase 6--metabolism; HeLa Cells; Humans; Mitogen-Activated Protein Kinase Phosphatases--antagonists & inhibitors; Models, Biological; Naphthoquinones--administration & dosage; Naphthoquinones--pharmacology; Paclitaxel--administration & dosage; Paclitaxel--pharmacology; Quinones--pharmacology; Reactive Oxygen Species--metabolism; Tumor Cells, Cultured |
PubMed ID: |
18245669 |
Date Deposited: |
01 Jul 2014 17:20 |
Last Modified: |
12 Jun 2021 22:55 |
URI: |
http://d-scholarship-dev.library.pitt.edu/id/eprint/20677 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
|
View Item |